Medtronic ($MDT) will report pivotal data for its Hybrid Closed Loop system for Type 1 diabetes on June 12 at the American Diabetes Association conference in New Orleans, LA. The data have been long-awaited and are expected to provide the basis for a submission to the FDA before the end of June. If it makes it past the agency, the system would be the first approved artificial pancreas--a highly anticipated development that would enable patients with diabetes to monitor blood glucose and automatically medicate with insulin based upon that real-time data. Medtronic is hoping to launch the device next spring. "We are proud to be the first company to present results of a pivotal trial of a closed loop system, which is designed to automatically control glucose levels 24 hours a day with less input from patients, as we continue toward our goal of helping people with diabetes enjoy greater freedom and better health," said Dr. Francine Kaufman, CMO and VP of global, clinical and medical affairs for Medtronic Diabetes, in a statement. More
> LabCorp ($LH) announced that the RealStar Zika Virus test is now available nationwide thanks to an Emergeny Use Authorization from the FDA. It is intended for the testing of individuals who meet EDE epidemiological criteria for Zika virus infection, which include travel to regions where Zika virus transmission is active. Release
> Zimmer Biomet ($ZBH) got an FDA warning letter dated May 27 for nonconformities with good manufacturing practice requirements at its Montreal manufacturing facility. Form 8K
> Ekso's ($ESKOD) robotic exoskeleton will gain connectivity from Vodafone's ($VOD) network and global Internet of Things SIM. The collaboration will ensure reliable communications for diagnostics and improve access to patient data. Release
> Switzerland's Biovotion announced the first closing of its Series A round, led by Swiss Re, and is in the process of adding more partners in a second closing. Release